Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial
Actinogen Medical Ltd has received a $9M R&D rebate from the Australian Taxation Office which will fund its activities through to mid-2026
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online